Skip to content
  • Home
  • About IPPI
    • Our Purpose
    • Team & Affiliates
    • Advisory Board
    • Funding & Support
    • Institutional Partners
    • History
  • Blog
    • IPPI Blog
    • List of All Blog Posts
  • Writing
    • Amicus Briefs
    • Letters, Comments, & Testimony
    • Policy Writing
    • Scholarship
  • Events
    • All Events
    • Conflicts Calendar
    • IPPI 2026 Winter Institute
      • 2026 Agenda
    • WIPO-U.S. Summer School on IP
      • 2026 Draft Agenda
  • Edison Fellowship
  • Contact
IPPI: The IP Policy Institute

IPPI: The IP Policy Institute

The University of Akron School of Law

[Archived Post] Professors Erika Lietzan and Kristina Acri Argue That Current Data Do Not Support Evergreening Allegations

Posted on: May 2, 2023May 13, 2026Biotech , Healthcare , Patents , Pharma

By Jack Ring In their forthcoming paper, Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations,[1] C-IP2 Senior Scholars Erika Lietzan of Mizzou Law […]

[Archived Post] C-IP2 Statement on Interactions between Courts and the FDA

Posted on: April 20, 2023May 13, 2026Pharma

Courts have recently questioned Food and Drug Administration (FDA) determinations. The FDA is the administrative agency whose job is to evaluate scientific data to determine if a drug is safe […]

[Archived Post] Policy Brief: The TRIPS Waiver for COVID-19 Vaccines, and Its Potential Expansion: Assessing the Impact on Global IP Protection and Public Health

Posted on: December 14, 2022May 13, 2026Patents , Pharma

This policy brief, including the following “Introduction and Executive Summary,” comes from Eric M. Solovy. CLICK HERE to read the brief in full. Introduction and Executive Summary On June 17, […]

[Archived Post] Reply and Response to C-IP2’s March 4, 2021, Blogpost on UC Hastings’ Evergreen Drug Patent Search Database

Posted on: September 14, 2021May 13, 2026Biotech , Patents , Pharma

C-IP2’s original post on the UC Hastings’ Evergreen Drug Patent Search Database can be read here. Reply to Blog Post on UC Hastings’ Evergreen Drug Patent Search Database Robin Feldman […]

[Archived Post] Panel Discussion: Vaccines, Intellectual Property, and Global Equity

Posted on: July 6, 2021May 13, 2026Biotech , C-IP2 News , International Law , Patents

The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at C-IP2.  The COVID-19 pandemic has shined a spotlight on the role of intellectual […]

[Archived Post] CPIP Scholars Join Comments to FTC on How Antitrust Overreach is Threatening Healthcare Innovation

Posted on: January 9, 2019May 13, 2026FTC , Healthcare

On December 21, 2018, CPIP Senior Scholars Adam Mossoff and Kristen Osenga joined former Federal Circuit Chief Judge Randall Rader and SIU Law’s Mark Schultz in comments submitted to the […]

[Archived Post] The Drug Innovation Paradox: Matching Incentives to Market Realities

Posted on: April 19, 2017May 13, 2026Innovation , Pharma

The hardest things are often the most important things. That’s one of the implicit justifications for the intellectual property system. If we want people to do the hard and important […]

[Archived Post] The Common Economic Case for Patents and Copyrights

Posted on: October 19, 2014May 13, 2026Biotech , Commercialization , Conferences , Copyright , Innovation , Intellectual Property Theory , Inventors , Uncategorized

This is the second in a series of posts summarizing CPIP’s 2014 Fall Conference, “Common Ground: How Intellectual Property Unites Creators and Innovators.” The Conference was held at George Mason […]

Recent Posts

  • Domestic Manufacturing as a Discretionary Consideration: Domestic Industry at the PTAB?
  • If AI Can Pirate the Internet, Why Can’t You?
  • Most-Favored-Nation (MFN) Drug Pricing: You Can’t Import European Prices Without Importing European Tradeoffs
  • IPPI 2026 Spring Progress Report
  • IPPI 2025 Winter Progress Report

Archives

Theme Alaska Blog by Kantipur Themes